Literature DB >> 22746011

New trends in the management of head and neck cancers.

Nayla Matar1, Amine Haddad.   

Abstract

Head and neck cancers affect more than half million person a year worldwide. More than 40% have an advanced stage at diagnosis. The incidence in Lebanon according to the statistics of the Ministry of Public Health was 268 new cases in 2007. The tumors and their treatment modalities have an important impact on the quality of life because they influence communication, breathing and4 swallowing. Treatment modalities are evolving to more conservative approaches for better functional results without impeding survival. We present in this review the state of the art of the management of head and neck cancer in 2011 with emphasis on the most recent advances in the assessment, treatment and follow-up.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22746011

Source DB:  PubMed          Journal:  J Med Liban        ISSN: 0023-9852


  4 in total

1.  DNA methylation biomarkers for head and neck squamous cell carcinoma.

Authors:  Chongchang Zhou; Meng Ye; Shumin Ni; Qun Li; Dong Ye; Jinyun Li; Zhisen Shen; Hongxia Deng
Journal:  Epigenetics       Date:  2018-08-10       Impact factor: 4.528

2.  NTF2 Upregulation in HNSCC: a Predictive Marker and Potential Therapeutic Target Associated With Immune Infiltration.

Authors:  Guangxu Xuan; Xin Zhang; Min Zhang; Minghang Yu; Yujie Zhou; Xiaosong He; Xiaopeng Hu; Xi Wang; Liangfa Liu
Journal:  Front Oncol       Date:  2022-06-17       Impact factor: 5.738

3.  The association, clinicopathological significance, and diagnostic value of CDH1 promoter methylation in head and neck squamous cell carcinoma: a meta-analysis of 23 studies.

Authors:  Zhisen Shen; Chongchang Zhou; Jinyun Li; Hongxia Deng; Qun Li; Jian Wang
Journal:  Onco Targets Ther       Date:  2016-10-31       Impact factor: 4.147

4.  Bioinformatics-based discovery of PYGM and TNNC2 as potential biomarkers of head and neck squamous cell carcinoma.

Authors:  Yu Jin; Ya Yang
Journal:  Biosci Rep       Date:  2019-07-29       Impact factor: 3.840

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.